Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

CellCentric’s $120 million Series C funding supports late-stage development of inobrodib, a novel oral p300/CBP inhibitor for multiple myeloma. Inobrodib’s mechanism targets MYC and IRF4 expression, ...

While multiple myeloma can be a challenging disease, there is hope for a better future. Continued research, improved treatments and strong support systems offer the potential for patients to live ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients have been told that multiple myeloma is treatable but not curable. Yet data ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

RAPA-201 is under development for the treatment of relapsed and refractory multiple myeloma, solid tumor, gastric cancer, head and neck cancer, carcinoma of unknown primary, bladder cancer, non-small ...

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy ...

Multiple myeloma is a type of blood cancer that happens in the bone marrow (the soft, spongy tissue inside the bones). Tecvayli attaches to a protein called BCMA that is found on the surface of ...

Potential reasons for delayed treatment initiation of guideline-directed oral medications to treat multiple myeloma (MM), and that demonstrate significant disparities to work at overcoming ...

Most people with multiple myeloma are diagnosed in their 60s, 70s or 80s. “Myeloma is predominantly a disease of aging, so the older you get, the more likely you are to get it,” Mohyuddin said.

Multiple myeloma is a rarer disease than other cancers, such as lung or breast cancer, an expert told CURE®. During the CURE® Educated Patient® Multiple Myeloma Summit, patients asked some questions ...